+ Watch CMN
on My Watchlist
The Company is a provider of infection prevention and control products in the healthcare market.
My 1y target for Cantel Medical Corp. (Symbol: CMN) is $ 37.07. It implies an increase of 9.28% of the share price (April 11 2014).
CMN TP 30 TP 38 1YR EPS 25%
From the value investor's perspective, Cantel stands out as a reliably impressive performer considering its ROE, ROA, 5 year trailing earnings growth, and quick ratio. In particular, the 25% 5 year trailing earnings growth (as of Nov 2013) really catches my attention compared to my other 8 medical device firms I'm watching.
(JJ) fundamentals good, health care sector+. NK thinks it's sexy.
This is one of my STARZ.Here is the thought process on this STAR: a) Divided rate over Zerob) 3 Year Beta between -5 & +3c) 15% + Insider ownershipd) No greater than -50% Growth rate for the last 3 years (tought= last couple of years so goo that insiders are still owning the stocks)e) Current CAPS rating between 3 Stars & 5 StarsOpen to all Industries and Sectors screened this down to just 250 stocks. I like round numbers. 12 of them I already own through other screening tools. I tend to be somewhat conservative but looking for 3 things at this point in my investing:1. Stability & Strength2. Yield and Modest Growth3. Strong Position within a sector regardless of whether the entire sector is strong or not. Each sector has to perform to some degree for the whole world economy to function. I am looking for 5 or more years down the road, ROI, and Growth.Not looking for rockets, just stars. This is a Star!!
A growing company in a growing field, with fear of infection in health care facilities, the future is shinning bright for CMN.
This looks like a very good entry point on this stock. it dropped 7% Thursday, but it's had 4 straight quarters of (large!) earnings surprises, and excellent growth of earnings, plus recent momentum in earnings estimates. It makes no sense that this stock is where it is. It is not widely followed, but I'd expect that to change.
I am big believer in any company that is associated with the medical industry because that company should always have something to sell and someone to buy.
Smart company moving to US from abroad. Maybe ALU should think about the same.
Member of the "Mini-Cap Monsters."
Cantel Medical Corp. is a leading provider of infection prevention and control products in the healthcare market. The company operates through four subsidiaries including Minntech, Crosstex, Mar Cor Purification and Saf-T-Pak. The company operates in six different segments through these subsidiaries which are: Dialysis, Endoscope Reprocessing and Therapeutic Filtration which are operated through Minntech, Dental operating segment operated through Crosstex, Water Purification and Filtration operated through Mar Cor Purification and Specialty Packaging operated through Saf-T-Pak.The company recently reported 9% increase in its revenues for the second quarter of 2007 as compared to the same period in 2006. The company divested the Carsen, its Canadian endoscope distribution business and is now fully focused on maintaining its leadership in infection prevention and control. It also recently entered into a distribution agreement for the MDS in the United Kingdom which is expected to increase its sales coverage and reduce operating costs. Additionally, with the shift in product mix achieved by the company over the past two quarters, over two-thirds of the company’s revenues are now recurring in nature.According to a research over 2.5 million people acquire an infection while in the care of a US healthcare facility every year costing the US healthcare system more than 5.5 billion annually. Additionally with an increased recurrence of drug-resistant staph infections otherwise know as MRSA or super-bugs and the threat of avian flu and bio terrorism offer tremendous opportunities for Cantel in the future. Moreover with the aging of the population in the US and developing countries, procedure growth continues in the endoscopy market which bodes well for the endoscope reprocessing business. Through the innovation of proprietary products and continued acquisitions, the company is well positioned to cash on these opportunities and it is expected that it will please the investors by its performance in the future.
Even though I like medical stocks, I don't think this one is a winner. :( --A Scientist
Perhaps all the bad news has already been factored in? Bit of a contrarian play here. Above the 200 day MA and has put in some strong up days.
New management, balance is not as bad as all these naysayers are putting forth... Give them a chance to recover, these guys are going to see more product/service orders over the next 5-10, demographics people - demographics! (hint: old people are not getting any younger)
i believe this one will outperform
I can't think of any bad news for Cantel. The services they provide are in demand. I will hold this for another 6 - 9 months.
I want to watch them after the bad report
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions